Brit boffins teach fusion plasma some manners with 3D magnetic field Summary Researchers at the UK Atomic Energy Authority (UKAEA) working on the MAST Upgrade spherical tokamak in Culham report…
Universities are embracing AI: will students get smarter or stop thinking? Article metadata Article Date: 2025-06-26 Article URL: https://www.nature.com/articles/d41586-025-03340-w Article Title: Universities are embracing AI: will students get smarter or…
The race for deep-sea minerals could cause geopolitical and ecological harm Summary The rapid roll-out of electric vehicles is driving interest in minerals that lie on the sea-bed. Recent policy…
Brazil must beef up its COP30 scheme to preserve tropical forests Summary Brazil plans to launch the Tropical Forest Forever Facility (TFFF) at COP30 in Belém — a scheme intended…
Feds flag active exploitation of patched Windows SMB vuln Summary CISA has added a high-severity Windows SMB client vulnerability (CVE-2025-33073) to its Known Exploited Vulnerabilities (KEV) catalogue on 20 October…
Opening Shot: The AWS Outage—A Glimpse into Cloud Chaos It was 12:11 AM PDT when AWS first acknowledged increased error rates and latencies in their US-EAST-1 region. What followed was…
AWS admits more bits of its cloud broke as it recovered from DynamoDB debacle Summary Amazon Web Services has confirmed that fixing a DNS problem that blocked access to a…
How scientists are pushing back against Trump’s funding ‘deal’ for universities Summary US President Donald Trump offered a higher-education “compact” that would align university admissions, hiring and research with administration…
People with blindness can read again after retinal implant Summary Scientists have used a tiny electronic retinal implant to restore useful central vision to people left functionally blind by advanced…
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers Article Meta Article Date: 20 October 2025 Article URL: https://www.nature.com/articles/s41586-025-09679-4 Article Image: Image Summary This Phase II NICHE study reports neoadjuvant nivolumab plus ipilimumab…
